Published in Vasc Health Risk Manag on January 01, 2007
Hydroxybenzoic acid isomers and the cardiovascular system. Nutr J (2014) 0.81
Partitioning of homologous nicotinic acid ester prodrugs (nicotinates) into dipalmitoylphosphatidylcholine (DPPC) membrane bilayers. Colloids Surf B Biointerfaces (2010) 0.75
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 15.39
Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 14.03
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 9.83
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ (1998) 7.48
Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA (1986) 7.23
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med (1998) 4.92
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2001) 4.21
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med (2005) 3.45
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2003) 3.43
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA (1990) 2.78
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis (1996) 2.70
High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis (1989) 2.65
Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ (1989) 2.47
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol (1988) 2.22
Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab (2002) 1.95
Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab (2001) 1.92
Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J (Clin Res Ed) (1981) 1.80
Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care (2005) 1.79
Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol (1997) 1.76
Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab (2004) 1.70
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol (1998) 1.28
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol (2002) 1.15
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.15
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.14
Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol (2000) 1.13
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis (2007) 1.13
Obesity and cardiovascular disease in developing countries: a growing problem and an economic threat. Curr Opin Clin Nutr Metab Care (2006) 1.11
Ageing, lifestyle modifications, and cardiovascular disease in developing countries. J Nutr Health Aging (2006) 1.09
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol (2003) 1.04
High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin (2005) 0.98
Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care (1998) 0.96
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol (2003) 0.94
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism (1998) 0.93
Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin (2006) 0.91
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol (2003) 0.91
Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med (2004) 0.90
Hepatotoxicity associated with sustained-release niacin. Am J Med (1992) 0.88
Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med (2007) 0.87
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol (2003) 0.86
Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial. J Cardiovasc Pharmacol Ther (1996) 0.86
Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol (2001) 0.85
Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol (1998) 0.84
Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol (2002) 0.80
Metabolic complications of antiretroviral therapy. Top HIV Med (2005) 0.80
Understanding niacin formulations. Am J Manag Care (2002) 0.79
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther (2006) 0.78
Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation (2006) 3.99
Clinical value of automatic reporting of estimated glomerular filtration rate in geriatrics. Gerontology (2008) 1.54
Iodine nutrition improves in Latin America. Thyroid (2004) 1.52
Serum neurotrophins--a study on the time course and influencing factors in a large old age sample. Neurobiol Aging (2006) 1.38
Efficacy of a vibrotactile neurofeedback training in stance and gait conditions for the treatment of balance deficits: a double-blind, placebo-controlled multicenter study. Otol Neurotol (2011) 1.19
Prevalence of obesity in primary care using different anthropometric measures--results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). BMC Public Health (2008) 1.13
A performance comparison of accelerometry-based step detection algorithms on a large, non-laboratory sample of healthy and mobility-impaired persons. Conf Proc IEEE Eng Med Biol Soc (2008) 1.06
Two-wave longitudinal findings from the Berlin aging study: introduction to a collection of articles. J Gerontol B Psychol Sci Soc Sci (2002) 0.99
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci (2011) 0.98
The Lower Saxony research network design of environments for ageing: towards interdisciplinary research on information and communication technologies in ageing societies. Inform Health Soc Care (2010) 0.97
Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet (2013) 0.96
MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain (2013) 0.94
Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs (2013) 0.89
The correlation between waist circumference and ESC cardiovascular risk score: data from the German metabolic and cardiovascular risk project (GEMCAS). Clin Res Cardiol (2008) 0.88
Nutrition status and pressure ulcer: what we need for nutrition screening. JPEN J Parenter Enteral Nutr (2007) 0.88
Cyanide poisoning and cardiac disorders: 161 cases. J Emerg Med (2010) 0.87
Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol (2005) 0.87
Mining geriatric assessment data for in-patient fall prediction models and high-risk subgroups. BMC Med Inform Decis Mak (2012) 0.86
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. J Med Genet (2012) 0.86
ICT-based health information services for elderly people: past experiences, current trends, and future strategies. Med Inform Internet Med (2007) 0.86
Psychological and sociodemographic predictors of premature discontinuation of a 1-year multimodal outpatient weight-reduction program: an attrition analysis. Patient Prefer Adherence (2012) 0.85
Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil (2005) 0.84
Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival. Int J Gynecol Cancer (2010) 0.84
Information and communication technologies for promoting and sustaining quality of life, health and self-sufficiency in ageing societies--outcomes of the Lower Saxony Research Network Design of Environments for Ageing (GAL). Inform Health Soc Care (2014) 0.84
Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. Biogerontology (2015) 0.84
Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial (2009) 0.84
Deep sedation during catheter ablation for atrial fibrillation in elderly patients. J Interv Card Electrophysiol (2013) 0.84
Impact of hip fracture, heart failure and weight loss on the risk of institutionalization of community-dwelling patients with dementia. Int J Geriatr Psychiatry (2008) 0.83
A prospective field study for sensor-based identification of fall risk in older people with dementia. Inform Health Soc Care (2014) 0.82
Physical fitness training in Subacute Stroke (PHYS-STROKE)--study protocol for a randomised controlled trial. Trials (2014) 0.82
Cytomegalovirus Infection Minimally Affects the Frequencies of B-Cell Phenotypes in Peripheral Blood of Younger and Older Adults. Gerontology (2016) 0.80
Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs (2012) 0.80
Comparison of four different mobile devices for measuring heart rate and ECG with respect to aspects of usability and acceptance by older people. Appl Ergon (2011) 0.80
Requirements of older adults for a daily use of an internet-based cognitive training platform. Inform Health Soc Care (2014) 0.79
Is there a role for mannan-binding lectin in the diagnosis of inflammatory bowel disease? Immunogenetics (2010) 0.79
Molecular characterization of familial hypercholesterolemia in German and Greek patients. Hum Mutat (2004) 0.79
Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J Neurol Sci (2005) 0.79
Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics (2014) 0.79
Evaluation of central auditory discrimination abilities in older adults. Front Aging Neurosci (2011) 0.78
Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. Neurogenetics (2011) 0.77
Implementation of a home-based interactive training system for fall prevention: requirements and challenges. J Gerontol Nurs (2014) 0.77
Editorial. Gerontology (2016) 0.76
Cohort Differences in Psychosocial Function over 20 Years: Current Older Adults Feel Less Lonely and Less Dependent on External Circumstances. Gerontology (2016) 0.76
The anticipatory proportion as an indicator of language impairment in early-stage cognitive disorder in the elderly. Dement Geriatr Cogn Disord (2013) 0.76
Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. Eur J Gastroenterol Hepatol (2017) 0.75
Interference of the cyanide antidote hydroxocobalamin with carboxyhemoglobin measurements should not limit clinical use in suspected or confirmed cyanide poisoning. Ann Emerg Med (2007) 0.75
Autosomal recessive hypercholesterolemia in three sisters with phenotypic homozygous familial hypercholesterolemia: diagnostic and therapeutic procedures. Ther Apher Dial (2004) 0.75
Sleep, Muscle Mass and Muscle Function in Older People. Dtsch Arztebl Int (2016) 0.75
New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. Wien Klin Wochenschr (2014) 0.75
Relative Leukocyte Telomere Length, Hematological Parameters and Anemia - Data from the Berlin Aging Study II (BASE-II). Gerontology (2016) 0.75
Prevalence of Impaired Kidney Function in the German Elderly: Results from the Berlin Aging Study II (BASE-II). Gerontology (2017) 0.75
Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice. Curr Med Res Opin (2012) 0.75
An ellipsometry-based Alzheimer plaque mimic: Effect of beta-amyloid, lipoprotein identity and apolipoprotein E isoform. J Colloid Interface Sci (2004) 0.75
In Reply. Dtsch Arztebl Int (2016) 0.75
[Lipid reduction without medication. What effect does diet have on lipids?]. Pharm Unserer Zeit (2003) 0.75
The Subjective Health Horizon Questionnaire (SHH-Q): Assessing Future Time Perspectives for Facets of an Active Lifestyle. Gerontology (2016) 0.75
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. Turk Kardiyol Dern Ars (2015) 0.75
Genetic Burden Analyses of Phenotypes Relevant to Aging in the Berlin Aging Study II (BASE-II). Gerontology (2016) 0.75
Advances in hemophilia care: report of two symposia at the Hemophilia 2010 World Congress. Adv Ther (2012) 0.75
Association between Metabolic Syndrome and Bone Mineral Density - Data from the Berlin Aging Study II (BASE-II). Gerontology (2016) 0.75
[Skin aging]. MMW Fortschr Med (2013) 0.75
Dusty punch cards and an eternal enigma: high-density lipoproteins and atherosclerosis. Drugs (2014) 0.75
Hydrogen cyanide poisoning in a prison environment: a case report. J Correct Health Care (2011) 0.75
Mild-to-Moderate Chronic Kidney Disease and Geriatric Outcomes: Analysis of Cross-Sectional Data from the Berlin Aging Study II. Gerontology (2017) 0.75